Here you will find the recommendations we have made about the use of individual medicines in Lancashire.


Brand: Firmagon ┬«
NICE TA: 404
Indication: Treatment of advanced hormone-dependent prostate cancer (NICE TA404)
Disease category: Malignant Disease
Commissioning responsibility: CCG
PbR excluded: No


Degarelix is recommended as an option for treating advanced hormone- dependent prostate cancer in people with spinal metastases, only if the commissioner can achieve at least the same discounted drug cost as that available to the NHS in June 2016. This guidance is not intended to affect the position of patients whose treatment with degarelix was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.


LMMG recommendation: Amber0
Click here to find the definitions for the colour classifications

Reason for decision:  Suitable for GP prescribing following recommendation/initiation by specialist

Supporting documents:

NICE TA404 - Degarelix for treating advanced hormone-dependent prostate cancer

Degarelix Prescribing Information Sheet (Version 1.0) (260.7 KiB)

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG